These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. Hu D; Sun Y J Am Coll Cardiol; 2008 Sep; 52(10):865-8. PubMed ID: 18755352 [No Abstract] [Full Text] [Related]
3. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. Selçuk H; Selçuk MT; Maden O Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079 [TBL] [Abstract][Full Text] [Related]
4. Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: ready for the prime time? Tzikas A; Freixa X; Ibrahim R Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1587-9. PubMed ID: 24215187 [No Abstract] [Full Text] [Related]
5. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Mant JW Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531 [No Abstract] [Full Text] [Related]
9. [Risk of thromboembolism in atrial fibrillation]. Csanádi Z Orv Hetil; 2016 Sep; 157(38):1511-5. PubMed ID: 27640617 [TBL] [Abstract][Full Text] [Related]
10. The need for new oral anticoagulants in clinical practice. Hylek EM J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764 [TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. Lang NN; Connelly DT J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359 [TBL] [Abstract][Full Text] [Related]
12. Blood pressure. The forgotten factor in previous and recent studies regarding anticoagulation in atrial fibrillation. Kallistratos MS; Manolis AJ; Mancia G Int J Cardiol; 2013 Oct; 168(4):4434-5. PubMed ID: 23890867 [No Abstract] [Full Text] [Related]
13. Bridging the gender gap in atrial fibrillation. Oza NM; Baveja S; Tedrow U Expert Rev Cardiovasc Ther; 2015 Mar; 13(3):317-23. PubMed ID: 25586881 [TBL] [Abstract][Full Text] [Related]
16. Ablation for atrial fibrillation: can we decrease thromboembolism without increasing the risk for bleeding? Asirvatham SJ Circulation; 2007 Nov; 116(22):2517-9. PubMed ID: 18040036 [No Abstract] [Full Text] [Related]
17. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Lip GY Europace; 2011 Feb; 13(2):145-8. PubMed ID: 21138929 [No Abstract] [Full Text] [Related]
18. Anticoagulation in people with atrial fibrillation. Fang MC BMJ; 2011 Jan; 342():d530. PubMed ID: 21282259 [No Abstract] [Full Text] [Related]
19. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Granger CB; Armaganijan LV Circulation; 2012 Jan; 125(1):159-64; discussion 164. PubMed ID: 22215890 [No Abstract] [Full Text] [Related]
20. [Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks]. Prisco D Haematologica; 2001 Sep; 86(9 Suppl):12-3. PubMed ID: 11759618 [No Abstract] [Full Text] [Related] [Next] [New Search]